Ireland - English - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - flucloxacillin sodium monohydrate - powder for solution for injection/infusion - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

esteve pharmaceuticals gmbh - flucloxacillin sodium - powder for solution for injection/infusion - 1000 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

Ireland - English - HPRA (Health Products Regulatory Authority)

esteve pharmaceuticals gmbh - flucloxacillin sodium - powder for solution for injection/infusion - 500 milligram(s) - beta-lactamase resistant penicillins; flucloxacillin

United States - English - NLM (National Library of Medicine)

bryant ranch prepack - dicloxacillin sodium (unii: 4hzt2v9kx0) (dicloxacillin - unii:cof19h7wbk) - to reduce the development of drug-resistant bacteria and maintain the effectiveness of dicloxacillin sodium capsules and other antibacterial drugs, dicloxacillin sodium capsules should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. dicloxacillin is indicated in the treatment of infections caused by penicillinase-producing staphylococci which have demonstrated susceptibility to the drug. cultures and susceptibility tests should be performed initially to determine the causative organisms and their sensitivity to the drug (see clinical pharmacology – susceptibility  testing ). dicloxacillin may be used to initiate therapy in suspected cases of resistant staphylococcal infections prior to the availability of laboratory test results. the penicillinase-resistant penicillins should not be used in infections caused by organisms susceptible to penicillin g. if the susceptibility tests indicate that the infection is due to an organism other than a resistant staphylococcus, therapy should not be continued with a penicillinase-resistant penicillin. dicloxacillin sodium is contraindicated in persons who have shown hypersensitivity to any of the penicillins or any component of the formulations.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - flucloxacillin sodium monohydrate, quantity: 545 mg (equivalent: flucloxacillin, qty 500 mg) - capsule, hard - excipient ingredients: povidone; titanium dioxide; purified talc; brilliant blue fcf; iron oxide red; magnesium stearate; iron oxide yellow; gelatin; microcrystalline cellulose; sodium starch glycollate - this product accepted for registration as 'currently supplied' at the time of commencement of the act. approval granted as specified in the letter of 1 may 1992 from dr h. arora. indicated for the treatment of confirmed or suspected staphylococcal and other gram-positive coccal infections including pneumonia, osteomyelitis, skin and soft tissue and wound infections, infected burns, cellulitis.

New Zealand - English - Medsafe (Medicines Safety Authority)

medra & pharma services limited - flucloxacillin sodium monohydrate 272mg equivalent to flucloxacillin 250 mg;  ;  ;  ;   - capsule - 250 mg - active: flucloxacillin sodium monohydrate 272mg equivalent to flucloxacillin 250 mg         excipient: magnesium stearate

New Zealand - English - Medsafe (Medicines Safety Authority)

medra & pharma services limited - flucloxacillin sodium monohydrate 544mg equivalent to flucloxacillin 500 mg;  ;  ;  ;   - capsule - 500 mg - active: flucloxacillin sodium monohydrate 544mg equivalent to flucloxacillin 500 mg         excipient: magnesium stearate

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - flucloxacillin sodium monohydrate 262.1mg equivalent to 250 mg flucloxicillin;   - powder for injection - 250 mg - active: flucloxacillin sodium monohydrate 262.1mg equivalent to 250 mg flucloxicillin  

New Zealand - English - Medsafe (Medicines Safety Authority)

hospira nz ltd - flucloxacillin sodium monohydrate 524.2mg equivalent to 500 mg flucloxicillin.;   - powder for injection - 500 mg - active: flucloxacillin sodium monohydrate 524.2mg equivalent to 500 mg flucloxicillin.  

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - flucloxacillin sodium - oral capsule - 250mg